On Monday, Black Diamond Therapeutics Inc (NASDAQ: BDTX) opened lower -3.10% from the last session, before settling in for the closing price of $2.58. Price fluctuations for BDTX have ranged from $1.20 to $6.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -5.22% over the last five years. Company’s average yearly earnings per share was noted 117.72% at the time writing. With a float of $43.28 million, this company’s outstanding shares have now reached $56.68 million.
The firm has a total of 24 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.75%, operating margin of -5.72%, and the pretax margin is 7.27%.
Black Diamond Therapeutics Inc (BDTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Black Diamond Therapeutics Inc is 23.88%, while institutional ownership is 61.96%. The most recent insider transaction that took place on Mar 19 ’25, was worth 11,997,749. In this transaction 10% Owner of this company sold 5,784,292 shares at a rate of $2.07, taking the stock ownership to the 2,733,547 shares. Before that another transaction happened on Aug 28 ’24, when Company’s 10% Owner sold 221,600 for $6.32, making the entire transaction worth $1,400,556. This insider now owns 3,726,341 shares in total.
Black Diamond Therapeutics Inc (BDTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 117.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.40% during the next five years compared to -5.22% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Check out the current performance indicators for Black Diamond Therapeutics Inc (BDTX). In the past quarter, the stock posted a quick ratio of 9.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.06, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.92 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Analysing the last 5-days average volume posted by the [Black Diamond Therapeutics Inc, BDTX], we can find that recorded value of 1.07 million was lower than the volume posted last year of 2.24 million. As of the previous 9 days, the stock’s Stochastic %D was 67.78%.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 82.28%, which indicates a significant increase from 61.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.71% in the past 14 days, which was lower than the 76.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.13, while its 200-day Moving Average is $2.42. Now, the first resistance to watch is $2.55. This is followed by the second major resistance level at $2.61. The third major resistance level sits at $2.67. If the price goes on to break the first support level at $2.44, it is likely to go to the next support level at $2.38. Now, if the price goes above the second support level, the third support stands at $2.32.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
There are currently 56,863K shares outstanding in the company with a market cap of 142.16 million. Presently, the company’s annual sales total 0 K according to its annual income of -69,680 K. Last quarter, the company’s sales amounted to 70,000 K and its income totaled 56,540 K.
